Mersana To Focus Fully On Anti-Cancer ADCs With $27M Recapitalization
This article was originally published in The Pink Sheet Daily
Executive Summary
Nearly ready to out-license its remaining small molecule drug conjugate candidate, Mersana will focus exclusively on developing Fleximer-based antibody-drug conjugates through collaborations with Endo and future partners.